Hualin Zhang

Dr. Hualin Zhang

Department of Radiation Oncology, University of Southern California, Uniontown, Pennsylvania, USA
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2020 in Radiation Research
Verified
Journal Article
Open access
PDF file
XWXiaodong Wu
Xiaodong Wu
NPNaipy C. Perez
Naipy C. Perez
YZYi Zheng
Yi Zheng
XLXiaobo Li
Xiaobo Li
LJLiuqing Jiang
Liuqing Jiang
CGChandan Guha
Chandan Guha
The concept of spatially fractionated radiation therapy (SFRT) was conceived over 100 years ago, first in the form of GRID, which has been applied to clinical practice since its early inception and continued to the present even with markedly improved instrumentation in radiation therapy. LATTICE radiation therapy (LRT) was introduced in 2010 as a conceptual 3D extension of GRID therapy with several uniquely different features. Since 2014, when the first patient was treated, over 150 patients with bulky tumors worldwide have received LRT. Through a brief review of the basic principles and the analysis of the collective clinical experience, a set of technical recommendations and guidelines are proposed for the clinical implementation of LRT. It is to be recognized that the current clinical practice of SFRT (GRID or LRT) is still largely based on the heuristic principles. With advancements in basic biological research and the anticipated clinical trials to systemically assess the efficacy and risk, progressively robust optimizations of the technical parameters are essential for the broader application of SFRT in clinical practice.

19 October 2020 in Radiation Research
Verified
Journal Article
Closed access
PDF file
Hualin ZhangHualin Zhang
Hualin Zhang
XWXiaodong Wu
Xiaodong Wu
XZXin Zhang
Xin Zhang
SCSha X. Chang
Sha X. Chang
AMAli Megooni
Ali Megooni
NMNina A. Mayr
Nina A. Mayr
The limits of radiation tolerance, which often deter the use of large doses, have been a major challenge to the treatment of bulky primary and metastatic cancers. A novel technique using spatial modulation of megavoltage therapy beams, commonly referred to as spatially fractionated radiation therapy (SFRT) (e.g., GRID radiation therapy), which purposefully maintains a high degree of dose heterogeneity across the treated tumor volume, has shown promise in clinical studies as a method to improve treatment response of advanced, bulky tumors. Compared to conventional uniform-dose radiotherapy, the complexities of megavoltage GRID therapy include its highly heterogeneous dose distribution, very high prescription doses, and the overall lack of experience among physicists and clinicians. Since only a few centers have used GRID radiation therapy in the clinic, wide and effective use of this technique has been hindered. To date, the mechanisms underlying the observed high tumor response and low toxicity are still not well understood. To advance SFRT technology and planning, the Physics Working Group of the Radiosurgery Society (RSS) GRID/Lattice, Microbeam and Flash Radiotherapy Working Groups, was established after an RSS-NCI Workshop. One of the goals of the Physics Working Group was to develop consensus recommendations to standardize dose prescription, treatment planning approach, response modeling and dose reporting in GRID therapy. The objective of this report is to present the results of the Physics Working Group's consensus that includes recommendations on GRID therapy as an SFRT technology, field dosimetric properties, techniques for generating GRID fields, the GRID therapy planning methods, documentation metrics and clinical practice recommendations. Such understanding is essential for clinical patient care, effective comparisons of outcome results, and for the design of rigorous clinical trials in the area of SFRT. The results of well-conducted GRID radiation therapy studies have the potential to advance the clinical management of bulky and advanced tumors by providing improved treatment response, and to further develop our current radiobiology models and parameters of radiation therapy design.

13 January 2010 in Cancer Research
Verified
Journal Article
Open access
PDF file
ZHZhibin Huang
Zhibin Huang
NMNina A. Mayr
Nina A. Mayr
WYWilliam T.C. Yuh
William T.C. Yuh
SLSimon S. Lo
Simon S. Lo
JMJoseph F. Montebello
Joseph F. Montebello
JWJian Z. Wang
Jian Z. Wang
Applications of mathematical modeling can improve outcome predictions of cancer therapy. Here we present a kinetic model incorporating effects of radiosensitivity, tumor repopulation, and dead-cell resolving on the analysis of tumor volume regression data of 80 cervical cancer patients (stages 1B2-IVA) who underwent radiation therapy. Regression rates and derived model parameters correlated significantly with clinical outcome (P < 0.001; median follow-up: 6.2 years). The 6-year local tumor control rate was 87% versus 54% using radiosensitivity (2-Gy surviving fraction S2 < 0.70 vs. S2 ≥ 0.70) as a predictor (P = 0.001) and 89% vs. 57% using dead-cell resolving time (T1/2 < 22 days versus T1/2 ≥ 22 days, P < 0.001). The 6-year disease-specific survival was 73% versus 41% with S2 < 0.70 versus S2 ≥ 0.70 (P = 0.025), and 87% vs. 52% with T1/2 < 22 days versus T1/2 ≥ 22 days (P = 0.002). Our approach illustrates the promise of volume-based tumor response modeling to improve early outcome predictions that can be used to enable personalized adaptive therapy. Cancer Res; 70(2); 463–70

1 June 2009 in Investigative Radiology
Verified
Journal Article
Closed access
WYWilliam T. C. Md Yuh
William T. C. Md Yuh
NMNina A. Mayr
Nina A. Mayr
DJDavid Jarjoura
David Jarjoura
DWDee Wu
Dee Wu
JGJohn C. Grecula
John C. Grecula
JWJian Z. Wang
Jian Z. Wang
Purpose: To assess the early predictive power of MRI perfusion and volume parameters, during early treatment of cervical cancer, for primary tumor control and disease-free-survival. Materials and Methods: Three MRI examinations were obtained in 101 patients before and during therapy (at 2–2.5 and 4–5 weeks) for serial dynamic contrast enhanced (DCE) perfusion MRI and 3-dimensional tumor volume measurement. Plateau Signal Intensity (SI) of the DCE curves for each tumor pixel of all 3 MRI examinations was generated, and pixel-SI distribution histograms were established to characterize the heterogeneous tumor. The degree and quantity of the poorly-perfused tumor subregions, which were represented by low-DCE pixels, was analyzed by using various lower percentiles of SI (SI%) from the pixel histogram. SI% ranged from SI2.5% to SI20% with increments of 2.5%. SI%, mean SI, and 3-dimensional volume of the tumor were correlated with primary tumor control and disease-free-survival, using Student t test, Kaplan-Meier analysis, and log-rank test. The mean post-therapy follow-up time for outcome assessment was 6.8 years (range: 0.2–9.4 years). Results: Tumor volume, mean SI, and SI% showed significant prediction of the long-term clinical outcome, and this prediction was provided as early as 2 to 2.5 weeks into treatment. An SI5% of <2.05 and residual tumor volume of ≥30 cm3 in the MRI obtained at 2 to 2.5 weeks of therapy provided the best prediction of unfavorable 8-year primary tumor control (73% vs. 100%, P = 0.006) and disease-free-survival rate (47% vs. 79%, P = 0.001), respectively. Conclusions: Our results show that MRI parameters quantifying perfusion status and residual tumor volume provide very early prediction of primary tumor control and disease-free-survival. This functional imaging based outcome predictor can be obtained in the very early phase of cytotoxic therapy within 2 to 2.5 weeks of therapy start. The predictive capacity of these MRI parameters, indirectly reflecting the heterogeneous delivery pattern of cytotoxic agents, tumor oxygenation, and the bulk of residual presumably therapy-resistant tumor, requires future study.

1 June 2010 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
NMNina A. Mayr
Nina A. Mayr
JWJian Z. Wang
Jian Z. Wang
DZDongqing Zhang
Dongqing Zhang
JGJohn C. Grecula
John C. Grecula
SLSimon S. Lo
Simon S. Lo
WYWilliam T.C. Yuh
William T.C. Yuh

17 December 2023 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
HLHeng Li
Heng Li
NMNina A. Mayr
Nina A. Mayr
RGRobert J. Griffin
Robert J. Griffin
Hualin ZhangHualin Zhang
Hualin Zhang
DPDamodar Pokhrel
Damodar Pokhrel
SBStanley H. Benedict
Stanley H. Benedict